Role of Systemic Inflammation in Increase of Cardio-vascular Risk in Chronic Obstructive Pulmonary Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02888886

Acronym

BPCO

Enrollment

Registered

2016-09-05

Start date

2007-07-31

Completion date

2015-11-30

Last updated

2016-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

systemic inflammation

Brief summary

The purpose is to study the correlation between systemic inflammation (serum levels of CRP, IL-1beta, IL-6 and TNF-alpha) or hyperhomocysteinemia and the increase of mortality, in a representative cohort of patients with chronic obstructive pulmonary disease (COPD). Secondary purposes are: 1. To confirm the increase of cardiovascular mortality and the importance of cardiovascular morbidity in patients with COPD, 2. To establish the role of various genetic polymorphisms in the correlation between systemic inflammation and cardiovascular disorders observed in COPD, 3. To search for acceleration of aging of cardiovascular system evaluated with carotid intima-media thickness when systemic inflammation markers are increased, 4. To study the correlation between COPD risk factors (tobacco and other food factors), change of respiratory functional data and cardiovascular morbi-mortality. In this study cardiovascular morbi-mortality is defined by following disorders: ischemic cardiopathy, left-sided heart failure, cardiac arrhythmia and cerebrovascular accident. Diagnosis is confirmed with standard techniques and independently of this study. Results of clinical examination, ECG, echocardiography and /or brain scanner will be collected.

Interventions

OTHERQuestionnaires about food habits and tobacco

OTHERSpirometry

OTHERCarotid echography

OTHERBlood sample

for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Actual or past active smoking of at least 20 packets/year * FEV1/FVC \< 70%

Exclusion criteria

* Co-morbidity except essential arterial hypertension controlled by treatment, stable coronary disease, type 2 diabetes and/or degenerative arthropathy (non-inflammatory rheumatic disorder) * Acute disorder during 8 weeks before inclusion, especially COPD worsening * Long-term corticosteroid or non-steroid anti-inflammatory treatment

Design outcomes

Primary

Measure	Time frame
Mortality	5 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026